Investor Events and Presentations | Takeda Pharmaceuticals
Investor Events
Contents
Earnings Announcement Meetings / IR Events / Broker Conferences
Quarterly Results - Quarter 3 FY2026
(January 28, 2027)
Quarterly Results - Quarter 4 FY2026
(May 13, 2027)
Event Archive
Zasocitinib (TAK-279) Investor Call on Phase 3 Psoriasis Data Presented at American Academy of Dermatology 2026
(6:30-7:30pm MDT, 8:30-9:30pm EDT on March 28, 2026)
TD Cowen 46th Annual Health Care Conference
(1:10-1:40pm EST on March 2, 2026)
Quarterly Results - Quarter 3 FY2025
(January 29, 2026)
44th Annual J.P. Morgan Healthcare Conference
(5:15 – 5:55pm PST on January 12, 2026)
Jefferies London Healthcare Conference
(2:30–2:55pm GMT, 9:30–9:55am EST on November 19, 2025)
- This event was closed.
Quarterly Results - Quarter 2 FY2025
(October 30, 2025)
Morgan Stanley Healthcare Conference
(3:20–3:55pm EDT on September 8, 2025)
- This event was closed.
Oveporexton (TAK-861) Investor Call on Phase 3 Narcolepsy Type 1 Data Presented at World Sleep 2025
(7:30-8:45pm SGT, 7:30-8:45am EDT on September 8, 2025)
Quarterly Results - Quarter 1 FY2025
(July 30, 2025)
Jefferies Global Healthcare Conference
(9:55-10:25am EDT on June 4, 2025)
- This event was closed.
Rusfertide Investor Call on Phase 3 Polycythemia Vera Data Presented at ASCO
(6:00-6:45 pm CDT on June 1, 2025)
Bank of America 2025 Health Care Conference
(4:20-4:35pm PDT on May 13, 2025)
Quarterly Results - Quarter 4 FY2024
(May 8, 2025)
TD Cowen 45th Annual Health Care Conference
(2:30-3:10pm EST on March 3, 2025)
- This event was closed.
Quarterly Results - Quarter 3 FY2024
(January 30, 2025)
43rd Annual J.P. Morgan Healthcare Conference
(1:30 – 2:10pm PST on January 14, 2025)
R&D Day: Focus on Late-Stage Pipeline and Market Opportunity
(6:30pm ~ EST on December 12, 2024)
Quarterly Results - Quarter 2 FY2024
(October 31, 2024)
Quarterly Results - Quarter 1 FY2024
(July 31, 2024)
TAK-861 Investor Call on Phase 2b Narcolepsy Type 1 Data
(7:30pm- 8:30pm CDT, 8:30pm - 9:30pm EDT on June 3, 2024)
Quarterly Results - Quarter 4 FY2023
(May 9, 2024)
Cowen 44th Health Care Conference
(9:50am – 10:20am EST on March 6, 2024)
- This event was closed.
Quarterly Results - Quarter 3 FY2023
(February 1, 2024)
42nd Annual J.P. Morgan Healthcare Conference
(5:15pm – 5:55pm PST on January 8, 2024)
- This event was closed.
Plasma-Derived Therapies Investor Event
(6:00 – 7:00pm EST on December 5, 2023)
Jefferies London Healthcare Conference
(4:00 – 4:25am EST on November 14, 2023)
(9:00 – 9:25am GMT on November 14, 2023)
- This event was closed.
Quarterly Results - Quarter 2 FY2023
(October 26, 2023)
Morgan Stanley Healthcare Conference
(3:35 – 4:05pm EDT on September 11, 2023)
- This event was closed.
Quarterly Results - Quarter 1 FY2023
(July 27, 2023)
Quarterly Results - Quarter 4 FY2022
(May 11, 2023)
TAK-279 (TYK2 inhibitor) Investor Call on Phase 2b Psoriasis Data
(March 18, 2023)
QDENGA Investor call
(March 15, 2023)
Cowen 43rd Health Care Conference
(March 6, 2023)
- This event was closed.
Quarterly Results - Quarter 3 FY2022
(February 2, 2023)
41st Annual J.P. Morgan Healthcare Conference
(January 9, 2023)
Conference call regarding acquisition of NDI-034858 From Nimbus Therapeutics
(December 13, 2022)
Jefferies London Healthcare Conference
(November 15, 2022)
- This event was closed.
Quarterly Results - Quarter 2 FY2022
(October 27, 2022)
Seminar: Investors and Analysts on Lysosomal Storage Diseases (LSD)
(October 4, 2022)
Morgan Stanley Healthcare Conference
(September 12, 2022)
- This event was closed.
Quarterly Results - Quarter 1 FY2022
(July 28, 2022)
Jefferies Healthcare Conference
(June 9, 2022)
- This event was closed.
Quarterly Results - Quarter 4 FY2021
(May 11, 2022)
Cowen 42nd Health Care Conference
(2:50pm – 3:20pm EST on March 8, 2022)
- This event was closed.
Seminar: Investors and Analysts on Short Bowel Syndrome (SBS) and Complex Crohn’s Perianal Fistulas (CPF)
(1:00pm JST on February 24, 2022)
Quarterly Results - Quarter 3 FY2021
(Held on February 3, 2022)
40th Annual J.P. Morgan Healthcare Conference
(4:30pm – 5:10pm EST on January 10, 2022)
Takeda Management Call
(6:00pm – 7:00pm EST on January 10, 2022)
Plasma-Derived Therapies Investor Event
(5:30pm – 7:30pm EST on November 17, 2021)
Quarterly Results - Quarter 2 FY2021
(Held on October 28, 2021)
Quarterly Results - Quarter 1 FY2021
(Held on July 30, 2021)
Finance Investor Day
(7:00pm – 9:00pm EDT on July 12, 2021)
Oncology Strategic Update Call
(6:30pm – 7:45pm EDT on June 8, 2021)
2021 Biopharma CEO Investor Forum
(8:00am – 8:50am EDT on June 7, 2021)
Wave 1 Pipeline Market Opportunity Call Part 2
(8:00am – 10:30am EDT on April 6, 2021)
Quarterly Results - Quarter 4 FY2020
(Held on May 11, 2021)
Growth and Emerging Markets Strategic Update Call
(6:30am-8:15am EST on March 11, 2021)
Seminar: Investors and Analysts on Takeda’s Japan Oncology Business and its oncology products and disease in Japan
(1:00pm-2:45pm JST on February 25, 2021)
Quarterly Results - Quarter 3 FY2020
(Held on February 4, 2021)
World Conference on Lung Cancer (WCLC) Investor Event
(5:00pm-6:00pm EST on January 29, 2021)
39th Annual J.P. Morgan Healthcare Conference
(5:20pm-6:00pm EST on January 11, 2021)
Wave 1 Pipeline Market Opportunity Call
(5:00pm-7:15pm EST on December 8, 2020)
Quarterly Results - Quarter 2 FY2020
(Held on October 29, 2020)
Seminar: Investors and Analysts on Inflammatory Bowel Disease
(1:00pm JST on September 2, 2020)
Quarterly Results - Quarter 1 FY2020
(Held on July 31, 2020)
Seminar: Investors and Analysts on Hereditary Angioedema (HAE)
(1:00pm JST on June 30, 2020)
Oncology Focused Investor Call
(8:00am EDT / 9:00pm JST on June 8, 2020)
Quarterly Results - Quarter 4 FY2019
(Held on May 13, 2020)
Quarterly Results - Quarter 3 FY2019
(Held on February 4, 2020)
38th Annual J.P. Morgan Healthcare Conference
(4:00pm-4:55pm PST on January 14, 2020)
R&D Day and Plasma-Derived Therapies Day in Tokyo
(11:00am-5:00pm JST on November 21, 2019)
Plasma-Derived Therapies
Plasma-Derived Therapies Overview: Julie Kim, President, Plasma-Derived Therapies Business Unit
Plasma-Derived Therapies R&D: Christopher Morabito, Head, R&D, Plasma-Derived Therapies
R&D Day
Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader: Christophe Weber, President & CEO
Translating Science into Highly Innovative, Life-changing Medicines: Andy Plump, President, R&D
Oncology and Cell Therapies with Spotlight on CAR-NK: Chris Arendt, Head, Oncology Drug Discovery Unit
Spotlight on Oncology Opportunities TAK-788: Rachael Brake, Global Program Leader, Oncology
Spotlight on Oncology Opportunities Pevonedistat: Phil Rowlands, Head, Oncology Therapeutic Area Unit
Rare Diseases & Gene Therapy: Dan Curran, Head, Rare Disease Therapeutic Area Unit
Spotlight on Orexin2R agonists: Deborah Hartman, Global Program Leader, Neuroscience
Therapeutic Area Focus in GI with Spotlight on Celiac Disease: Asit Parikh, Head, GI Therapeutic Area Unit
Plasma-Derived Therapies Day in Covington, Georgia
(11:15am-3:45pm EST on November 15, 2019)
Plasma-Derived Therapies Overview: Julie Kim, President, Plasma-Derived Therapies Business Unit
Plasma-Derived Therapies R&D: Christopher Morabito, Head, R&D, Plasma-Derived Therapies
Covington Site Introduction: Carlos Soto, Covington Site Head
R&D Day in New York
(12:30pm-4:00pm EST on November 14, 2019)
Welcome and Opening Remarks: Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy
Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader: Christophe Weber, President & CEO
Translating Science into Highly Innovative, Life-changing Medicines: Andy Plump, President, R&D
Oncology and Cell Therapies with Spotlight on CAR-NK: Chris Arendt, Head, Oncology Drug Discovery Unit
Spotlight on Oncology Opportunities TAK-788: Rachael Brake, Global Program Leader, Oncology
Spotlight on Oncology Opportunities Pevonedistat: Phil Rowlands, Head, Oncology Therapeutic Area Unit
Rare Diseases & Gene Therapy: Dan Curran, Head, Rare Disease Therapeutic Area Unit
Spotlight on Orexin2R agonists: Deborah Hartman, Global Program Leader, Neuroscience
Therapeutic Area Focus in GI with Spotlight on Celiac Disease: Asit Parikh, Head, GI Therapeutic Area Unit
Quarterly Results - Quarter 2 FY2019
(Held on October 31, 2019)
IR meeting with analysts and investors with Julie Kim, President of Takeda's Plasma-Derived Therapies Business Unit
(Held on October 10, 2019)
- This event was closed.
Morgan Stanley Healthcare Conference
(Held on September 10, 2019 ET)
- This event was closed.
Quarterly Results - Quarter 1 FY2019
(Held on July 31, 2019)
IR Seminar “Plasma-Derived Therapies Business”
(Held on July 12, 2019)
Quarterly Results - Quarter 4 FY2018
(Held on May 14, 2019)
Quarterly Results - Quarter 3 FY2018
(Held on February 1, 2019)
37th Annual J.P. Morgan Healthcare Conference
(Held on January 8, 2019 PST)
Meeting regarding Acquisition of Shire plc by Takeda
(Held on January 7, 2019)
Presentation: A Global, Values-based, R&D-driven Biopharmaceutical Leader
Quarterly Results - Quarter 2 FY2018
(Held on October 31, 2018)
Takeda’s R&D Investor Day (Boston)
(October 11, 2018)
Presentation: Delivering on our R&D vision
Andy Plump, Chief Medical and Scientific Officer
Takeda’s R&D Investor Day (Tokyo)
(September 27, 2018)
Presentation: Delivering on our R&D vision
Andy Plump, Chief Medical and Scientific Officer
Quarterly Results - Quarter 1 FY2018
(Held on July 31, 2018)
Quarterly Results - Quarter 4 FY2017
(Held on May 14, 2018)
Conference Call Regarding Proposed Acquisition of Shire plc by Takeda
(Held on May 8/9, 2018)
- Presentation: Takeda to Acquire Shire-Accelerating Takeda’s Transformation to Deliver More for Patients
Quarterly Results - Quarter 3 FY2017
(Held on February 1, 2018)
36th Annual J.P. Morgan Healthcare Conference
(Held on January 8, 2018 PST)
Jefferies 2017 Global Healthcare Conference
(Presented November 16, 2017, 10:00 GMT)
- This event was closed.
Quarterly Results - Quarter 2 FY2017
(Held on November 1, 2017)
Quarterly Results - Quarter 1 FY2017
(Held on July 28, 2017)
UBS Global Healthcare Conference
(Released on May 23, 2017, 9:30 EDT)
- This event was closed.
Quarterly Results - Quarter 4 FY2016
(Held on May 10, 2017)
Quarterly Results - Quarter 3 FY2016
(Held on February 1, 2017)
Conference Call on the Acquisition of ARIAD Pharmaceuticals
(Released on January 10, 2017)
35thAnnual J.P. Morgan Healthcare Conference
(Held on January 9, 2017)
Quarterly Results - Quarter 2 FY2016
(Held on October 28, 2016)
Quarterly Results - Quarter 1 FY2016
(Held on July 29, 2016)
Takeda IR Day
(Held on June 9, 2016)
Takeda Oncology: Christophe Bianchi, President, Global Oncology Business Unit
Focused World Class R&D New approaches to innovation: Andrew Plump, Chief Medical & Scientific Officer
Quarterly Results - Quarter 4 FY2015
(Held on May 10, 2016)
Quarterly Results - Quarter 3 FY2015
(Held on February 3, 2016)
34th Annual J.P. Morgan Healthcare Conference
(Held on January 12, 2016)
Quarterly Results - Quarter 2 FY2015
(Held on October 30, 2015)
Quarterly Results - Quarter 1 FY2015
(Held on July 30, 2015)
Quarterly Results - Quarter 4 FY2014
(Held on May 15, 2015)
Takeda IR Event: A Global Leader in Gastroenterology
(Held on March 9, 2015)
Quarterly Results - Quarter 3 FY2014
(Held on February 5, 2015)
33rd Annual J.P. Morgan Healthcare Conference
(Held on January 13, 2015)
Quarterly Results - Quarter 2 FY2014
(Held on October 30, 2014)
Quarterly Results - Quarter 1 FY2014
(Held on August 1, 2014)
Quarterly Results - Quarter 4 FY2013
(Held on May 8, 2014)
Quarterly Results - Quarter 3 FY2013
(Held on February 5, 2014)
32nd Annual J.P. Morgan Healthcare Conference
(Held on January 13, 2014)
Quarterly Results - Quarter 2 FY2013
(Held on October 31, 2013)
Quarterly Results - Quarter 1 FY2013
(Held on July 31, 2013)
150th Annual General Meeting of Shareholders (June 24, 2026)
Notice of Convocation of the 150th Annual General Meeting of Shareholders
Planned Revision of Consolidated Financial Statements Related to a Subsequent Event
Notice of Resolutions at the 150th Annual General Meeting of Shareholders
Results of the Exercise of Voting Rights of the 150th Annual General Meeting of Shareholders
Past Shareholder Events & Reports
Retail Investor Events
Online information session for retail investors: "Committed to Growth & Shareholder Returns" (in Japanese only)
7:45 pm - 8:30 pm JST on February 22, 2024
Information session for retail investors: "Better health for people, Brighter future for the world"
February 22, 2023
Sign up for our investors newsletter
As we move forward in a new era for Takeda, stay up to date through our newsletter, featuring our business strategy, progress in research and development,
and how we are leveraging AI and other digital technologies to drive innovation.
You can also receive email updates on our press releases, investor events, and more.